Robert Langer insider trades: Rubius Therapeutics (RUBY) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Robert reports to the SEC
and 15 more companies
Open-market buys and sales
21 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 14, 2019 | RUBY | ↓ Sell | 7,500 | $8.52 | $64K | Direct | Oct 17, 2019 (3d) |
| Jul 15, 2019 | RUBY | ↓ Sell | 7,500 | $14.94 | $112K | Direct | Jul 17, 2019 (2d) |
| Apr 15, 2019 | RUBY | ↓ Sell | 7,500 | $17.57 | $132K | Direct | Apr 17, 2019 (2d) |
| Jan 14, 2019 | RUBY | ↓ Sell | 7,500 | $14.59 | $109K | Direct | Jan 18, 2019 (4d) |
| Jun 5, 2013 | NVIV | ↓ Sell | 7,500 | $3.73 | $28K | Direct | Jun 5, 2013 (0d) |
| May 31, 2013 | NVIV | ↓ Sell | 7,500 | $3.31 | $25K | Direct | May 31, 2013 (0d) |
| May 28, 2013 | NVIV | ↓ Sell | 7,500 | $2.97 | $22K | Direct | May 28, 2013 (0d) |
| May 22, 2013 | NVIV | ↓ Sell | 7,500 | $2.88 | $22K | Direct | May 22, 2013 (0d) |
| May 17, 2013 | NVIV | ↓ Sell | 7,500 | $2.85 | $21K | Direct | May 17, 2013 (0d) |
| May 14, 2013 | NVIV | ↓ Sell | 7,500 | $2.91 | $22K | Direct | May 14, 2013 (0d) |
| May 9, 2013 | NVIV | ↓ Sell | 7,500 | $2.91 | $22K | Direct | May 9, 2013 (0d) |
| May 6, 2013 | NVIV | ↓ Sell | 7,500 | $3.02 | $23K | Direct | May 6, 2013 (0d) |
| May 1, 2013 | NVIV | ↓ Sell | 7,500 | $3.12 | $23K | Direct | May 1, 2013 (0d) |
| Apr 26, 2013 | NVIV | ↓ Sell | 7,500 | $2.92 | $22K | Direct | Apr 26, 2013 (0d) |
| Jan 17, 2013 | NVIV | ↓ Sell | 190,735 | $2.47 | $470K | Direct | Jan 17, 2013 (0d) |
| Jul 2, 2012 | NVIV | ↓ Sell | 45,000 | $2.34 | $105K | Direct | Jul 2, 2012 (0d) |
| Jun 28, 2012 | NVIV | ↓ Sell | 155,000 | $2.41 | $373K | Direct | Jun 28, 2012 (0d) |
| Apr 16, 2012 | NVIV | ↓ Sell | 200,000 | $2.40 | $480K | Direct | Apr 17, 2012 (1d) |
| Dec 29, 2011 | NVIV | ↓ Sell | 165,247 | $2.49 | $411K | Direct | Jan 3, 2012 (5d) |
| Aug 8, 2008 | MNTA | ↓ Sell | 20,000 | $16.81 | $336K | Direct | Aug 11, 2008 (3d) |
| Jan 30, 2007 | SONT | ↑ Buy | 250,000 | $0.10 | $25K | Direct | Jan 31, 2007 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Robert Langer's insider trades
Robert Langer is a director at Rubius Therapeutics (RUBY). Since Jan 30, 2007, Robert has reported 1 open-market purchase worth $25K and 20 sales worth $2.8M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (72 filings), option exercises (6 filings), shares returned to the company (4 filings), conversions (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RUBY insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.